Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal.Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its acquisition…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
